表觀遺傳學診斷市場－全球產業規模、佔有率、趨勢、機會、預測：按產品、應用、技術、地區和競爭對手分類，2021-2031年

全球表觀遺傳診斷市場預計將從 2025 年的 148.1 億美元成長到 2031 年的 239.2 億美元，複合年成長率為 8.32%。

該領域專注於分析基因表現中可遺傳的變化，例如DNA甲基化和組蛋白修飾，以在不改變DNA序列本身的情況下檢測疾病生物標記。推動這一領域發展的關鍵因素是個人化醫療範圍的擴大和標靶治療法規核准的持續成功。這些因素都要求精確的分子譜分析，以便選擇有效的治療方法。例如，根據個人化醫療聯盟的報告，FDA在2024年核准了18種新的個人化藥物。這表明這些針對特定患者的治療方法正在迅速應用於臨床實踐，同時也凸顯了對先進診斷技術進行精準患者分層的迫切需求。

然而，該市場面臨與研發和實施檢測高成本相關的重大挑戰。尤其是在醫療體系低度開發的國家，複雜的報銷機制和不一致的保險覆蓋政策對先進的分子診斷構成了嚴重的經濟障礙。這些經濟限制因素可能會限制表觀遺傳學檢測的普及，並阻礙市場的強勁成長。因此，解決這些經濟挑戰對於先進診斷工具的廣泛應用以及市場維持長期成長至關重要。

市場促進因素

癌症和慢性疾病的日益普及是全球表觀遺傳診斷市場的主要驅動力，也因此需要比傳統切片檢查更靈敏的先進檢測方法。隨著這些疾病在全球範圍內的負擔不斷加重，醫療專業人員對錶觀遺傳分析的興趣日益濃厚，希望藉此識別症狀出現前就已存在的甲基化標記和組蛋白修飾。近期的一些預測也印證了這種迫切性。根據美國癌症協會於2025年1月發布的《2025年癌症事實與數據》報告，預計僅在美國就將新增2,041,910例癌症病例。如此高的發病率表明，亟需能夠對疾病進行早期分層的分子診斷技術，而市場也需要持續創新才能滿足不斷成長的患者群體的需求。

同時，對非侵入性液態生物檢體診斷的需求激增，透過減少對侵入性組織取樣的依賴，正在改變市場動態。基於表觀遺傳學的液態生物檢體背後是顯著的商業性成長。 2025年2月，Guardant Health在其2024年第四季及全年財報中披露，其全年營收成長31%至7.39億美元，凸顯了其液態生物檢體平台的廣泛應用。此外，Exact Sciences在2025年2月宣布，其2024年全年營收已達27.6億美元，證實了該領域領先的診斷服務提供者所取得的巨大經濟規模以及在臨床實踐中的廣泛應用。

市場挑戰

開發檢測方法的高昂成本，加上不穩定的醫保報銷環境，對全球表觀遺傳診斷市場的擴張構成了重大障礙。儘管表觀遺傳生物標記的科學有效性不斷提高，但這些複雜檢測方法的商業化資金籌措來源仍不明朗。實驗室必須投入大量資金來檢驗和實施先進的檢測平台，但往往面臨保險公司報銷範圍不一致和收費系統限制等問題，這些都無法彌補前期投入。這種經濟上的差距迫使診斷服務提供者在擴展檢測項目方面猶豫不決，從而有效地阻礙了表觀遺傳學研究成果轉化為可用的臨床工具。

這種財務不穩定限制了檢測實驗室的持續營運和創新能力。據美國臨床實驗室協會 (ACLA) 稱，聯邦政府持續實施價格管制預計將導致 2024 年約 800 項臨床檢測的報銷額度降低高達 15%。如此巨大的收入威脅迫使診斷公司採取極其謹慎的行動，這往往導致先進的表觀遺傳學檢測產品上市延遲或規模有限。因此，這些根深蒂固的經濟限制因素直接阻礙了市場成長，減少了檢測服務的可近性，並阻礙了將這些複雜診斷技術整合到標準患者照護中所需的投資。

市場趨勢

市場參與者正擴大採用機器學習演算法和深度學習模型來解讀複雜的DNA甲基化數據，從而加速生物標記的發現，並超越傳統統計方法，顯著提高疾病預測的準確性。這些人工智慧驅動的平台對於識別龐大基因組資料集中的細微甲基化特徵至關重要，而這種能力對於多癌症種早期檢測的商業性銷售量得益於其底層機器學習分類器，該分類器能夠分析甲基化模式，從而預測癌症訊號的來源。

儘管腫瘤學仍是主要關注領域，但市場正呈現出將表觀遺傳分析應用於神經退化性疾病、心血管疾病和老齡化相關疾病的明顯趨勢。這一轉變源於人們日益認知到，在複雜的慢性疾病中，表觀遺傳修飾往往領先臨床症狀出現，這為早期風險分層和干涉提供了獨特的機會，其應用範圍已超越腫瘤學領域。為了支持這項不斷擴展的應用範圍，Pacific Biosciences 在 2025 年 11 月發布的 2025 年第三季財報新聞稿中宣布，其 Revio定序系統已被美國國家老齡研究所 (NIA) 的「長壽家族研究」計畫所採用。該研究將對多達 7,800 名個體進行全基因組和表觀基因定序，以揭示健康老齡化的分子決定因素。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球表觀遺傳學診斷市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 產品類別（試劑、試劑盒（晶片定序試劑盒、全基因組擴增試劑盒、亞硫酸氫鹽轉化試劑盒、RNA定序試劑盒、其他）、儀器、酵素、服務）
  • 依應用領域（腫瘤科（固體癌等）、非腫瘤科（發炎性疾病、代謝疾病、感染疾病、心血管疾病等））
  • 透過技術手段（DNA甲基化、組蛋白甲基化、組蛋白乙醯化、大非編碼RNA、 微型RNA修飾）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美表觀遺傳學診斷市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲表觀遺傳學診斷市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區表觀遺傳學診斷市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲表觀遺傳學診斷市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲表觀遺傳學診斷市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球表觀遺傳學診斷市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Roche Diagnostics
• Thermo Fisher Scientific, Inc.
• Eisai Co. Ltd.
• Novartis AG
• Element Biosciences, Inc.
• Dovetail Genomics LLC.
• Illumina, Inc.
• ValiRx Plc.
• Abcam plc

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Epigenetics Diagnostics Market is projected to expand from USD 14.81 Billion in 2025 to USD 23.92 Billion by 2031, registering a compound annual growth rate of 8.32%. This sector focuses on analyzing heritable changes in gene expression, such as DNA methylation and histone modification, to detect disease biomarkers without altering the DNA sequence itself. A primary driver of this growth is the widening scope of personalized medicine and the increasing regulatory success of targeted therapies, which demand precise molecular profiling for effective treatment selection. For instance, the Personalized Medicine Coalition reported that in 2024, the FDA approved 18 new personalized medicines, indicating the rapid integration of these tailored interventions into clinical practice and highlighting the urgent need for advanced diagnostic methodologies to accurately stratify patient populations.

However, the market faces significant hurdles related to the high costs of test development and implementation. The complex reimbursement landscape and inconsistent coverage policies for advanced molecular diagnostics, particularly within developing healthcare systems, create substantial financial barriers. These economic constraints limit the widespread accessibility of epigenetic testing and threaten to impede the robust expansion of the market. Consequently, addressing these financial challenges is essential to ensure that advanced diagnostic tools become broadly available and to sustain the market's long-term growth trajectory.

Market Driver

The escalating prevalence of cancer and chronic diseases acts as a primary catalyst for the Global Epigenetics Diagnostics Market, driving the need for advanced detection methods that offer higher sensitivity than traditional biopsies. As the global burden of these pathologies grows, healthcare providers are increasingly turning to epigenetic profiling to identify methylation markers and histone modifications that appear before symptoms manifest. This urgency is supported by recent projections; according to the American Cancer Society's "Cancer Facts & Figures 2025" report from January 2025, it is estimated that 2,041,910 new cancer cases will be diagnosed in the United States alone. Such rising incidence rates underscore the critical necessity for molecular diagnostics capable of early disease stratification, compelling the market to innovate continuously to meet the needs of an expanding patient base.

Simultaneously, the surging demand for non-invasive liquid biopsy diagnostics is reshaping market dynamics by reducing dependence on invasive tissue sampling. Epigenetic-based liquid biopsies, which detect circulating tumor DNA (ctDNA) methylation patterns, are seeing rapid adoption because they provide real-time insights into disease progression and treatment response with minimal patient risk. This shift toward blood-based testing is evidenced by significant commercial growth; Guardant Health reported in February 2025, within its "Fourth Quarter and Full Year 2024 Financial Results," a 31% increase in full-year revenue to $739 million, highlighting the expanding use of liquid biopsy platforms. Furthermore, Exact Sciences announced in February 2025 that it generated revenue of $2.76 billion for the full year 2024, confirming the substantial economic scale and widespread clinical integration achieved by leading diagnostic providers in this sector.

Market Challenge

The prohibitive cost of test development combined with a volatile reimbursement landscape creates a formidable barrier to the expansion of the Global Epigenetics Diagnostics Market. Although the scientific validity of epigenetic biomarkers continues to mature, the financial pathways to commercialize these complex assays remain uncertain. Laboratories must invest substantial capital to validate and implement sophisticated testing platforms, yet they frequently encounter inconsistent payer coverage and restrictive fee schedules that fail to offset these initial expenditures. This economic disconnect discourages diagnostic providers from expanding their test menus, effectively stalling the translation of epigenetic research into accessible clinical tools.

This financial instability limits the ability of laboratories to sustain operations and innovate. According to the American Clinical Laboratory Association, approximately 800 clinical laboratory tests faced scheduled reimbursement reductions of up to 15 percent in 2024 due to the ongoing implementation of federal pricing regulations. Such significant threats to revenue streams compel diagnostic companies to act with extreme caution, often delaying the launch of advanced epigenetic panels or restricting them to limited markets. Consequently, these deep-seated economic constraints directly stifle market growth by reducing the availability of testing services and deterring the investment necessary to integrate these precise diagnostics into standard patient care.

Market Trends

Market players are increasingly deploying machine learning algorithms and deep learning models to interpret complex DNA methylation data, accelerating biomarker discovery and improving disease prediction accuracy beyond traditional statistical methods. These AI-driven platforms are essential for distinguishing subtle methylation signatures across vast genomic datasets, a capability that is critical for the commercial scalability of multi-cancer early detection assays. This technological reliance is substantiated by recent operational metrics; according to GRAIL, Inc.'s "Third Quarter 2025 Financial Results" released in November 2025, the company sold more than 45,000 tests of its Galleri multi-cancer early detection assay during the quarter, a volume made possible by the underlying machine-learning classifiers that analyze methylation patterns to predict cancer signal origin.

While oncology remains the dominant focus, the market is witnessing a distinct trend toward utilizing epigenetic profiling for neurodegenerative disorders, cardiovascular diseases, and aging-related conditions. This shift is driven by the growing recognition that epigenetic modifications often precede clinical symptoms in complex chronic diseases, offering a unique window for early risk stratification and intervention outside the cancer space. Highlighting this expanded research scope, Pacific Biosciences announced in a November 2025 press release regarding its "Third Quarter 2025 Financial Results" that its Revio sequencing system was selected for the National Institute on Aging's Long Life Family Study to sequence up to 7,800 whole genomes and epigenomes to investigate the molecular determinants of healthy aging.

Key Market Players

• Roche Diagnostics
• Thermo Fisher Scientific, Inc.
• Eisai Co. Ltd.
• Novartis AG
• Element Biosciences, Inc.
• Dovetail Genomics LLC.
• Illumina, Inc.
• ValiRx Plc.
• Abcam plc

Report Scope

In this report, the Global Epigenetics Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Epigenetics Diagnostics Market, By Product

• Reagents
• Kits
• Instruments
• Enzymes
• Services

Epigenetics Diagnostics Market, By Application

• Oncology
• Non-oncology

Epigenetics Diagnostics Market, By Technology

• DNA Methylation
• Histone Methylation
• Histone Acetylation
• Large noncoding RNA
• MicroRNA modification

Epigenetics Diagnostics Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Epigenetics Diagnostics Market.

Available Customizations:

Global Epigenetics Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Epigenetics Diagnostics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Reagents, Kits (Chip Sequencing Kit, Whole Genomic Amplification kit, Bisulfite Conversion Kit, RNA Sequencing Kit, Others), Instruments, Enzymes, Services)
  • 5.2.2. By Application (Oncology (Solid Tumors, Others), Non-oncology (Inflammatory Diseases, Metabolic Diseases, Infectious Diseases, Cardiovascular Diseases, Others))
  • 5.2.3. By Technology (DNA Methylation, Histone Methylation, Histone Acetylation, Large noncoding RNA, MicroRNA modification)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Epigenetics Diagnostics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Application
  • 6.2.3. By Technology
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Epigenetics Diagnostics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By Technology
  • 6.3.2. Canada Epigenetics Diagnostics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By Technology
  • 6.3.3. Mexico Epigenetics Diagnostics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By Technology

7. Europe Epigenetics Diagnostics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Application
  • 7.2.3. By Technology
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Epigenetics Diagnostics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By Technology
  • 7.3.2. France Epigenetics Diagnostics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By Technology
  • 7.3.3. United Kingdom Epigenetics Diagnostics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By Technology
  • 7.3.4. Italy Epigenetics Diagnostics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By Technology
  • 7.3.5. Spain Epigenetics Diagnostics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By Technology

8. Asia Pacific Epigenetics Diagnostics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Application
  • 8.2.3. By Technology
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Epigenetics Diagnostics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By Technology
  • 8.3.2. India Epigenetics Diagnostics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By Technology
  • 8.3.3. Japan Epigenetics Diagnostics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By Technology
  • 8.3.4. South Korea Epigenetics Diagnostics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By Technology
  • 8.3.5. Australia Epigenetics Diagnostics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By Technology

9. Middle East & Africa Epigenetics Diagnostics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Application
  • 9.2.3. By Technology
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Epigenetics Diagnostics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By Technology
  • 9.3.2. UAE Epigenetics Diagnostics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By Technology
  • 9.3.3. South Africa Epigenetics Diagnostics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By Technology

10. South America Epigenetics Diagnostics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Application
  • 10.2.3. By Technology
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Epigenetics Diagnostics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By Technology
  • 10.3.2. Colombia Epigenetics Diagnostics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By Technology
  • 10.3.3. Argentina Epigenetics Diagnostics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By Technology

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Epigenetics Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Roche Diagnostics
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Thermo Fisher Scientific, Inc.
• 15.3. Eisai Co. Ltd.
• 15.4. Novartis AG
• 15.5. Element Biosciences, Inc.
• 15.6. Dovetail Genomics LLC.
• 15.7. Illumina, Inc.
• 15.8. ValiRx Plc.
• 15.9. Abcam plc

16. Strategic Recommendations

17. About Us & Disclaimer